Emily Rogalski1, Jaiashre Sridhar2, Benjamin Rader2, Adam Martersteck2, Kewei Chen2, Derin Cobia2, Cynthia K Thompson2, Sandra Weintraub2, Eileen H Bigio2, M-Marsel Mesulam2. 1. From the Cognitive Neurology and Alzheimer's Disease Center (E.R., J.S., B.R., A.M., C.K.T., S.W., M.-M.M.) and Departments of Psychiatry and Behavioral Sciences (D.C., S.W.), Neurology (C.K.T., M.-M.M.), and Pathology (E.H.B.), Northwestern University Feinberg School of Medicine, Chicago, IL; Banner Alzheimer's Institute (K.C.), Phoenix, AZ; and Department of Communication Sciences Disorders (C.K.T.), Northwestern University, Evanston, IL. erogalski@gmail.com. 2. From the Cognitive Neurology and Alzheimer's Disease Center (E.R., J.S., B.R., A.M., C.K.T., S.W., M.-M.M.) and Departments of Psychiatry and Behavioral Sciences (D.C., S.W.), Neurology (C.K.T., M.-M.M.), and Pathology (E.H.B.), Northwestern University Feinberg School of Medicine, Chicago, IL; Banner Alzheimer's Institute (K.C.), Phoenix, AZ; and Department of Communication Sciences Disorders (C.K.T.), Northwestern University, Evanston, IL.
Abstract
OBJECTIVE: To identify features of primary progressive aphasia (PPA) associated with Alzheimer disease (AD) neuropathology. A related objective was to determine whether logopenic PPA is a clinical marker for AD. METHODS: A total of 139 prospectively enrolled participants with a root diagnosis of PPA constituted the reference set. Those with autopsy or biomarker evidence of AD, and who had been evaluated at mild disease stages (Aphasia Quotient ≥85), were included (n = 19). All had quantitative language testing and APOE genotyping. Fifteen had MRI morphometry. RESULTS: Impaired word-finding was the universal presenting complaint in the aphasic AD group. PPA clinical subtype was logopenic (n = 13) and agrammatic (n = 6). Fluency, repetition, naming, and grammaticality ranged from preserved to severely impaired. All had relative preservation of word comprehension. Eight of the 15 aphasic participants with AD showed no appreciable cortical atrophy at the individual level on MRI. As a group, atrophy was asymmetrically concentrated in the left perisylvian cortex. APOE ε4 frequency was not elevated. CONCLUSIONS: There is a close, but not obligatory, association between logopenic PPA and AD. No language measure, with the possible exception of word comprehension, can confirm or exclude AD in PPA. Biomarkers are therefore essential for diagnosis. Asymmetry of cortical atrophy and normal APOE ε4 prevalence constitute deviations from typical AD. These and additional neuropathologic features suggest that AD has biological subtypes, one of which causes PPA. Better appreciation of this fact should promote the inclusion of individuals with PPA and positive AD biomarkers into relevant clinical trials.
OBJECTIVE: To identify features of primary progressive aphasia (PPA) associated with Alzheimer disease (AD) neuropathology. A related objective was to determine whether logopenic PPA is a clinical marker for AD. METHODS: A total of 139 prospectively enrolled participants with a root diagnosis of PPA constituted the reference set. Those with autopsy or biomarker evidence of AD, and who had been evaluated at mild disease stages (Aphasia Quotient ≥85), were included (n = 19). All had quantitative language testing and APOE genotyping. Fifteen had MRI morphometry. RESULTS: Impaired word-finding was the universal presenting complaint in the aphasic AD group. PPA clinical subtype was logopenic (n = 13) and agrammatic (n = 6). Fluency, repetition, naming, and grammaticality ranged from preserved to severely impaired. All had relative preservation of word comprehension. Eight of the 15 aphasic participants with AD showed no appreciable cortical atrophy at the individual level on MRI. As a group, atrophy was asymmetrically concentrated in the left perisylvian cortex. APOE ε4 frequency was not elevated. CONCLUSIONS: There is a close, but not obligatory, association between logopenic PPA and AD. No language measure, with the possible exception of word comprehension, can confirm or exclude AD in PPA. Biomarkers are therefore essential for diagnosis. Asymmetry of cortical atrophy and normal APOE ε4 prevalence constitute deviations from typical AD. These and additional neuropathologic features suggest that AD has biological subtypes, one of which causes PPA. Better appreciation of this fact should promote the inclusion of individuals with PPA and positive AD biomarkers into relevant clinical trials.
Authors: M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman Journal: Neurology Date: 2011-02-16 Impact factor: 9.910
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Ankit V Master; Val J Lowe; Clifford R Jack; Jennifer L Whitwell Journal: Brain Date: 2012-03-01 Impact factor: 13.501
Authors: M-Marsel Mesulam; Bradford C Dickerson; Janet C Sherman; Daisy Hochberg; R Gilberto Gonzalez; Keith A Johnson; Matthew P Frosch Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: Emily Joy Rogalski; Jaiashre Sridhar; Adam Martersteck; Benjamin Rader; Derin Cobia; Anupa K Arora; Angela J Fought; Eileen H Bigio; Sandra Weintraub; Marek-Marsel Mesulam; Alfred Rademaker Journal: Alzheimers Dement Date: 2019-02-11 Impact factor: 21.566
Authors: Miguel A Santos-Santos; Gil D Rabinovici; Leonardo Iaccarino; Nagehan Ayakta; Gautam Tammewar; Iryna Lobach; Maya L Henry; Isabel Hubbard; Maria Luisa Mandelli; Edoardo Spinelli; Zachary A Miller; Peter S Pressman; James P O'Neil; Pia Ghosh; Andreas Lazaris; Marita Meyer; Christa Watson; Soo Jin Yoon; Howard J Rosen; Lea Grinberg; William W Seeley; Bruce L Miller; William J Jagust; Maria Luisa Gorno-Tempini Journal: JAMA Neurol Date: 2018-03-01 Impact factor: 18.302
Authors: David Bergeron; Maria L Gorno-Tempini; Gil D Rabinovici; Miguel A Santos-Santos; William Seeley; Bruce L Miller; Yolande Pijnenburg; M Antoinette Keulen; Colin Groot; Bart N M van Berckel; Wiesje M van der Flier; Philip Scheltens; Jonathan D Rohrer; Jason D Warren; Jonathan M Schott; Nick C Fox; Raquel Sanchez-Valle; Oriol Grau-Rivera; Ellen Gelpi; Harro Seelaar; Janne M Papma; John C van Swieten; John R Hodges; Cristian E Leyton; Olivier Piguet; Emily J Rogalski; Marsel M Mesulam; Lejla Koric; Kristensen Nora; Jeéreémie Pariente; Bradford Dickerson; Ian R Mackenzie; Ging-Yuek R Hsiung; Serge Belliard; David J Irwin; David A Wolk; Murray Grossman; Matthew Jones; Jennifer Harris; David Mann; Julie S Snowden; Patricio Chrem-Mendez; Ismael L Calandri; Alejandra A Amengual; Carole Miguet-Alfonsi; Eloi Magnin; Giuseppe Magnani; Roberto Santangelo; Vincent Deramecourt; Florence Pasquier; Niklas Mattsson; Christer Nilsson; Oskar Hansson; Julia Keith; Mario Masellis; Sandra E Black; Jordi A Matías-Guiu; María-Nieves Cabrera-Martin; Claire Paquet; Julien Dumurgier; Marc Teichmann; Marie Sarazin; Michel Bottlaender; Bruno Dubois; Christopher C Rowe; Victor L Villemagne; Rik Vandenberghe; Elias Granadillo; Edmond Teng; Mario Mendez; Philipp T Meyer; Lars Frings; Alberto Lleó; Rafael Blesa; Juan Fortea; Sang Won Seo; Janine Diehl-Schmid; Timo Grimmer; Kristian Steen Frederiksen; Pascual Sánchez-Juan; Gaël Chételat; Willemijn Jansen; Rémi W Bouchard; Robert Jr Laforce; Pieter Jelle Visser; Rik Ossenkoppele Journal: Ann Neurol Date: 2018-11 Impact factor: 10.422
Authors: Eliana Marisa Ramos; Deepika Reddy Dokuru; Victoria Van Berlo; Kevin Wojta; Qing Wang; Alden Y Huang; Zachary A Miller; Anna M Karydas; Eileen H Bigio; Emily Rogalski; Sandra Weintraub; Benjamin Rader; Bruce L Miller; Maria Luisa Gorno-Tempini; Marek-Marsel Mesulam; Giovanni Coppola Journal: Alzheimers Dement Date: 2019-01-25 Impact factor: 21.566